INTRODUCTION
The Cognard classification is a commonly used system for categorizing dural arteriovenous fistulas (DAVFs), 1 based on the drainage pattern of fistulas, which is the most important predictor of the affected patient's clinical presentation. [1] [2] [3] [4] Cognard type IV lesions drain directly into ectatic cortical veins, with absent dural venous drainage, therefore carrying a much higher risk of hemorrhage and requiring aggressive management. 1 DAVFs in the anterior cranial fossa differ from other subtypes because the arterial supply is fed preferentially by ethmoidal branches of the ophthalmic artery (OphA). [5] [6] [7] [8] [9] [10] [11] As there is no dural sinus in this location, these fistulas drain directly into the frontal cortical veins, 5 6 8 and the proportion of anterior cranial fossa DAVFs classified as Cognard type IV is much higher than other subtypes. 5 7 Treatment of DAVFs with cortical venous drainage is aimed at complete occlusion of the fistula and can be surgical, endovascular, or occasionally, a combination. [9] [10] [11] [12] [13] [14] During the past two decades, embolization by using transarterial, transvenous, or combined approaches has become a firstline treatment for DAVFs. [12] [13] [14] [15] [16] [17] Recently, the use of Onyx (ev3, Irvine, California, USA) via the arterial route for the treatment of DAVFs has been increasingly reported with promising results. 6 7 18-20 Although treatment of Cognard type IV anterior cranial fossa with arterial injection of Onyx have been reported sporadically, 6 7 9-11 there are few case series which have paid special attention to the techniques, outcomes, and complications of transarterial treatment with Onyx for these lesions. We present our experience in the management of these lesions using the transarterial approach with Onyx.
MATERIALS AND METHODS Patients
Between October 2009 and October 2011, six consecutive patients diagnosed with Cognard type IV anterior cranial fossa DAVFs were initially treated transarterially with Onyx for curative purposes. Diagnosis was confirmed after angiography of all cerebral vessels. Patient characteristics are summarized in table 1. All patients were male; mean age was 55 years (range 38-68).
Clinical presentation
Four patients (case Nos 1, 2, 3, and 6) presented with intracranial hemorrhage and the fifth patient (case No 4) had recurrent seizures at the time of diagnosis, which were unrelated to acute hemorrhage. The patient presenting with seizures refused both surgical and endovascular treatment but used antiepileptic drugs to control seizures until intracranial hemorrhage occurred. The remaining patient (case No 5) was asymptomatic, and the lesion was discovered incidentally by MRI performed for unrelated reasons. The clinical symptoms of these six patients are presented in table 1.
Preoperative radiologic evaluation
Preoperative planar images (CT, MRI, or both) had been obtained in all six patients. Intracranial hemorrhage was evident in five of these (case Nos 1, 2, 3, 4, and 6) before treatment. Large draining veins with definite venous pouches were seen in all cases. Before the treatment procedure, digital subtraction angiography (DSA) was performed in all cases to confirm the diagnosis and angiographic characteristics, and to assist treatment planning. In one patient (case No 3) there was, in addition to an anterior DAVF, a second DAVF located in the middle part of the cerebral falx. One patient (case No 4) had an arterial aneurysm located on the OphA proximal to the fistula. The numbers of venous aneurysms on each draining vein were counted. Angiographic characteristics of these lesions are summarized in table 2.
Treatment
All procedures consisted of transarterial embolization using Onyx with the patient under general anesthesia. Anticoagulation during the treatment process included an intravenous bolus of 3000 IU of heparin given at the beginning of each procedure, and heparin used in the flushing system of the guiding catheter (3000 IU/l of saline).Vascular access was obtained via a transfemoral approach using a 6 French guiding catheter. Sometimes when the lesion was fed by bilateral arteries, the contralateral transfemoral approach was also obtained to perform control angiograms to evaluate the degree of fistula occlusion during the procedure. Firstly, diagnostic angiography was performed to delineate the vascular architecture of the lesions. Following the diagnostic angiogram, using a roadmapping technique, a Marathon microcatheter was coaxially navigated through the guiding catheter into a selected feeding artery. Progression of the microcatheter was aided by the use of a microguidewire (Mirage 008, ev3 or Traxcess-14, Microvention) to reach to or as close as possible to the fistula. DAVFs in this location usually receive an arterial blood supply from the ethmoidal branches of the OphAs, sometimes from branches of the middle meningeal artery (MMA), sphenopalatine artery of the internal maxillary artery, etc. This can present technical challenges to superselective navigation of the microcatheter because the routes are usually tortuous. In two cases in this series, after failure to navigate the microcatheter to the desired position using the Mirage 008 microguidewire, we used the Traxcess-14 microguidewire instead because of its better supporting and guiding properties. We successfully navigated the microcatheter. Hence replacement of a more suitable microguidewire is recommended and sometimes helpful for successful navigation. Occasionally, extreme patience is needed to navigate the microcatheter to the desired position.
When a safe embolization position was achieved, superselective angiography was performed to reveal the focal angioarchitecture and dynamic flow behavior of the fistula. After superselective angiogram analysis, the microcatheter was then prepared with dimethyl sulfoxide in a standard manner. Under constant fluoroscopic visualization, Onyx 18 or 34 was then slowly infused into the fistulas. The decision regarding which concentration of Onyx to use was subjective and was based on the distance from the arteriovenous shunt, flow velocity of the shunt and risk of venous migration. Onyx was injected into the fistula and was stopped when consistent reflux was noted. Subsequent injections were reinitiated after waiting for a few seconds to 2 min. A plug of Onyx around the distal part of the microcatheter was created by slow injection of Onyx, in between periods of rest. This plug prevents further Onyx reflux and allows vascular connections to be opened between different compartments, enabling its penetration into the fistular compartments. Once Onyx advanced into the fistular compartments, it was intermittently injected until the draining veins, sometimes including the venous pouches, were filled and thereby completely occluding the fistula. Usually this reflux reinjection process needed to be repeated several times before Onyx advanced into the fistula site. During the process of intermittent injection, the operator should pay attention to the direction of penetration of Onyx and the stability of Onyx in the draining veins, or venous aneurysms, to make sure the normal arteries safe and Onyx in the draining veins is stable and will not cause embolic complications. Control angiograms were obtained during the procedure and at the end of the treatment session to evaluate the degree of fistula occlusion. The duration of Onyx injections was calculated from time prints on the angiographic images. The amount of injected Onyx was obtained from the embolization records. Five lesions in this series were embolized through unilateral or bilateral ophthalmic arteries. In these five cases, the microcatheter was advanced as close as possible to the fistulas, with no evidence of choroidal blush on superselective angiography. The origin of the central retinal artery must be kept in mind, with the aim of not embolizing the central retinal artery by Onyx reflux. Illustrative cases are provided in figures 1 and 2.
Follow-up protocol
Patient followup was performed clinically and angiographically, preferably using DSA. MR angiography was regarded as an alternative in cases where DSA was not available. A treatment was considered to be curative when complete fistula obliteration had been achieved, as verified on follow-up DSA or MR angiography.
RESULTS
The overall results of the management of Cognard type IV anterior cranial fossa DAVFs in this case series are summarized in table 3.
It was possible to completely occlude the fistulas with Onyx via arterial feeders in a single session in five patients (case Nos 2, 3, 4, 5, and 6), resulting in complete cure. In the remaining case, subtotal occlusion was achieved because Onyx injected from the right OphA and the anterior branch of the left MMA did not retrogradely occlude the feeders of the left sphenopalatine artery and these residual feeders were too thin to catheterize. This patient underwent gamma knife treatment 4 months after the embolization treatment. In case Nos 5 and 6, a single unilateral OphA injection was sufficient to occlude the venous site of the fistula with retrograde occlusion of other arterial feeders; in case Nos 3 and 4, bilateral OphA injections were needed; and in one patient, the anterior branch of the right MMA and the bilateral orbitofrontal branches of the anterior cerebral artery injections were needed. In five cases (case Nos 1, 3, 4, 5, and 6), removal of the microcatheter was uneventful. In case No 2, it was difficult to retrieve the microcatheter after injecting Onyx into the anterior branch of the right MMA, and the distal part of the microcatheter was entrapped. Fortunately, hemorrhage did not occur during retrieval of the microcatheter and there was no subsequent complication associated with retention of the distal part of the microcatheter in this case. Two cases (case Nos 2 and 6) experienced transient postprocedural chemosis and retro-orbital discomfort, which were restored to normal during the follow-up period. There were no other complications of treatment.
Clinically, all patients improved after treatment at the follow-up period. At clinical follow-up, case Nos 1 and 2 presented with intermittent headache; case No 3 presented with memory loss and mild disorientation; case 4 presented with weakness of the left limbs; case No 5 was asymptomatic; and case no 6 presented with depression. No mortality or permanent severe morbidity was observed in this series. The recurrent seizures in case No 4 were controlled with medical treatment after embolization. Follow-up DSA or MR angiography obtained in case Nos 2, 3, 4, 5, and 6 confirmed durable obliteration of the fistulas. The case who underwent radiosurgical treatment was waiting for DSA follow-up. No patient suffered intracranial hemorrhage during the follow-up period.
DISCUSSION
DAVFs in the anterior cranial fossa are rare but they have a high incidence of sudden massive intracranial hemorrhage because these fistulas usually drain directly into the ectatic frontal cortical veins (associated with venous aneurysms) and are termed Cognard type IV DAVFs. Many treatment approaches to these lesions have been proposed, including surgery, stereotactic radiosurgery (SRS) and endovascular therapy, either by the transarterial or transvenous approach (table 4) . 5-7 9-12 15 21-26 Neurosurgery is a traditionally recommended treatment approach. 12 17 However, due to the risks inherent in craniotomy and the efficacy of endovascular treatment, surgery is currently only indicated in cases where endovascular approaches have failed or are not feasible. 17 27 28 For stereotactic radiosurgery, the hemorrhage risk remains elevated until completion of vessel thrombosis, so it is inappropriate as the primary treatment in Cognard type IV DAVFs. 25 In our department, the transvenous endovascular approach is rarely used for these lesions because of the tortuosity and fragility of the leptomeningeal veins and the risk of rupture during selective catheterization. In our center, the transarterial approach for these lesions was the preferred choice. Transarterial embolization for Cognard type IV anterior cranial fossa DAVFs is aimed at complete elimination of the arteriovenous shunt-incomplete treatment allows recruitment of collateral vessels and the persistent risk of hemorrhage. New embolic materials, such as Onyx, have recently been developed and are considered to represent a type of 'gold standard' for embolization of DAVFs because of their advantages over traditional agents, including greater control of the embolic agent during injection, injection time, and overall high cure rate with few complications. 6 7 18 19 The advantageous characteristics of Onyx made the reflux reinjection technique, also called plug creating technique, possible in embolizing these fistulas with Onyx transarterially. Recently, the use of Onyx via the arterial route for treatment of anterior cranial fossa DAVFs has been sporadically reported with promising results. 6 7 9-11 However, to the best of our knowledge, the literature is sparse, reporting mostly case reports. 6 9-11 Mack et al 6 reported two cases in which anterior cranial fossa DAVFs were treated exclusively using transarterial embolization strategies with Onyx and N-butyl cyanoacrylate. Tahon et al 9 reported an association of the Onyx liquid embolic system and the Sonic microcatheter for transarterial embolization through the anterior branch of the MMA of a DAVF of the anterior fossa. Another two case reports described the treatment of three anterior cranial fossa fistulas with Onyx. [10] [11] Related case series reports are fewer. Abud et al 7 reported a series of 42 patients with 44 DAVFs treated by transcatheter injection of Onyx using the arterial approach, and four of the DAVFs were described as Cognard type IV anterior cranial fossa DAVFs but they did not particular attention to the techniques, outcomes, or complications of this treatment for these special lesions. In our case series, five of six lesions were cured after initial transarterial embolization with Onyx, and our experience in the treatment of these lesions via arterial injection of Onyx is hopeful.
Injection via the OphA route was most often used when embolizing these lesions transarterially. Navigation of the microcatheter as close as possible to the fistulas is more important 6 4 TA/Onyx (6) Nil nBCA, N-butyl cyanoacrylate; Nil, without access to relevant information; TA, transarterial approach; TV, transvenous approach.
through this route than through other routes because only satisfactory catheterization can provide enough reflux distance to apply the reflux reinjection technique and ensure the safety of the central retinal artery simultaneously during Onyx injection.
No evidence of choroidal blush on superselective angiography is mandatory before Onyx injection. The origin of central retinal artery should be kept in mind and close attention should be paid during Onyx injection to ensure that Onyx reflux does not embolize the central retinal artery. Removal of the microcatheter was relatively safe after injecting Onyx via the OphA, despite long segments of reflux, and this was beneficial to achieve complete obliteration. In this case series, five lesions were treated by the unilateral or bilateral OphA route and none of these patients was complicated by impairment of vision after the procedure.
CONCLUSIONS
Our experience with the use of Onyx for arterial embolization of Cognard type IV anterior cranial fossa DAVFs is encouraging, with complete cure in most lesions without severe complications. The reasonable use of related techniques is the way to obtain promising results.
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